ASCO GU 2025

What's the role of Enzalutamide in radioligand therapy?

Combining ARPi with PARPi - discussing final OS of…

Who benefits most from ARPIs?

MDT in OMPC

ARPI for which patients?

Local radiotherapy of oligoprogressive mCRPC

Hypo-gonadism bad for survival?

ENZA-p showed OS benefit and improvement in QoL…

Durvalumab in UTUC

Darolutamide + ADT reduces risk of progression or death…

Final OS data for TALA + Enza

Mevrometostat + Enza: New option for mCRPC

Fish-oil supplement for pts on active surveillance

Final OS analyses

Darolutamide + ADT and Doetaxel improves survivas in…

Testosterone Recovery

Testosterone Recovery after ADT and OS

OS in the TALAPRO-2 trial

Improved Survival with Enzalutamide + Lutetium

Radiation vs surgery in high risk prostate cancer

Phase 2 Mevrometostat

Radical Prostatectomy VS RT in HRPC

Oligometastatik PCa da MDT

Hangi hastalarda ADT+ARPI

Enza+Lu ile artmis sagkalim

UTUC de Neoadj. Durvalumab+Kemo

Testosteron Geri Gelisi ve Sagkalim

Triplet combination in RCC - there's no free lunch with…

New data but no new conclusion

KIM-1 - The most interesting biomarker for RCC?

Casdatifan in refracting RCC

AVION trial at mRCC

KIM-1 in mRCC

Advanced Renal Cell Cancer: Adding more drugs does not…

KIM-1 in CheckMate 214

New agents / new mode of actions

Prognostic and predictive biomarkers in mRCC: Looking…

New data nccRCC

Firstline Update Kidney Cancer

Cáncer de células renales avanzado: añadir más fármacos…

Neoadjuvant chemo-immunotherapy in UTUC: new evidence…

Reassuring data on established ADCs and new insights in…

New data, but no new insights for adjuvant treatment of…

ADC + ICI - The future for MIBC?

EV-Pembro continues to be the standard for mTCC

The role of ctDNA in bladder cancer

Bladder-sparing approaches - are we there yet?

Phase 2 Mevrometastat

Promising combination for perioperative setting

New FGFR3 inhibitor

Neoadjuvant treatment for UTUC

New drugs in mUC: The active field of ADCs

Nivo adjuvant in MIBC - a new standard

HER2 - new marker for bladder preservation

Durvalumab + Platinum-based chemotherapy shows…

Updates neo/adjuvant therapy in MIBC

Adjuvant Nivo - independent from previous therapy

ASCO GU 25 - Summary: Urothelial Cancer

Sacituzumab Tirumotecan shows promising antitumor…

Preliminary results of neoadjuvant chemoimmunotherapy…

Nuevos fármacos en mUC: El campo activo de las ADCs

Promising combination for perioperative setting

RPLND in metastatic Seminoma

Cáncer de testículo: reinventar la rueda